Abstract:Abstract Background Human immunodeficiency virus type 1 (HIV-1) remains a persistent global health challenge. Therefore, a continuous exploration of novel therapeutic strategies is essential. A comprehensive understanding of how HIV-1 utilizes the cellular metabolism machinery for replication can provide insights into new therapeutic approaches. Methods In this study, we performed a flux balance analysis using a genome-scale metabolic model (GEM) integrated with an HIV-1 viral biomass objective function to identify potential targets for anti–HIV-1 interventions. We generated a GEM by integrating an HIV-1 production reaction into CD4+ T cells and optimized for both host and virus optimal states as objective functions to depict metabolic profiles of cells in the status for optimal host biomass maintenance or for optimal HIV-1 virion production. Differential analysis was used to predict biochemical reactions altered optimal for HIV-1 production. In addition, we conducted in silico simulations involving gene and reaction knock-outs to identify potential anti–HIV-1 targets, which were subsequently validated by human phytohemagglutinin (PHA) blasts infected with HIV-1. Results Differential analysis identified several altered biochemical reactions, including increased lysine uptake and oxidative phosphorylation (OXPHOS) activities in the virus optima compared with the host optima. In silico gene and reaction knock-out simulations revealed de novo pyrimidine synthesis, and OXPHOS could serve as potential anti–HIV-1 metabolic targets. In vitro assay confirmed that targeting OXPHOS using metformin could suppress the replication of HIV-1 by 56.6% (385.4 ± 67.5 pg/mL in the metformin-treated group vs. 888.4 ± 32.3 pg/mL in the control group, P < 0.001). Conclusion Our integrated host-virus genome-scale metabolic study provides insights on potential targets (OXPHOS) for anti-HIV therapies.

HIV-1 Infection and Glucose Metabolism Reprogramming of T Cells: Another Approach Toward Functional Cure and Reservoir Eradication

Research progress on HIV latency-reversing agents and its mechanism

Killing HIV-infected Resting Central Memory CD4+ T Cells by Targeting Inhibitor of Apoptosis Proteins-Inhibited Autophagy

Moving Toward a Functional Cure for HIV-1

Metabolic reprogramming of immune cells in HIV infection and treatment

Functional cure for HIV:the approaches and challenges

Flux Balance Analysis Reveals Potential Anti–HIV-1 Metabolic Targets

HIV-1 Latency and Viral Reservoirs: Existing Reversal Approaches and Potential Technologies, Targets, and Pathways Involved in HIV Latency Studies

Immune targeting of HIV-1 reservoir cells: a path to elimination strategies and cure

Altering cell death pathways as an approach to cure HIV infection

Examining Chronic Inflammation, Immune Metabolism, and T Cell Dysfunction in HIV Infection

Elevated glutamate impedes anti-HIV-1 CD8 + T cell responses in HIV-1-infected individuals on antiretroviral therapy

Targeting Viral Transcription for HIV Cure Strategies

Progress and Challenges in the Use of Latent HIV-1 Reactivating Agents

HIV-1 functional cure: will the dream come true?

The Rational Combination Strategy of Immunomodulatory Latency Reversing Agents and Novel Immunotherapy to Achieve HIV-1 Cure

Tat-Based Therapies as an Adjuvant for an HIV-1 Functional Cure

Functional Restoration of Exhausted CD8 T Cells in Chronic HIV-1 Infection by Targeting Mitochondrial Dysfunction

Immune Checkpoint Molecules and Glucose Metabolism in HIV-Induced T Cell Exhaustion

Insights into the HIV-1 Latent Reservoir and Strategies to Cure HIV-1 Infection